CV Sciences, Inc. (CVSI) stock
CVSIOTCPharmaceutical PreparationsFiscal year ends December 31
$0.01−0.00 (-21.13%)
Close on Oct 19, 2026Market cap $2.53MP/E –Yield –
CV Sciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
CV Sciences's operating income for the twelve months ending Sep 30, 2026 was -$317.00K. For fiscal 2025 it was -$470.00K. The highest annual figure on record is $10.25M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$470.00K | – |
| FY2024 | Dec 31, 2024 | -$2.19M | -165.2% |
| FY2023 | Dec 31, 2023 | $3.36M | – |
| FY2022 | Dec 31, 2022 | -$6.85M | – |
| FY2021 | Dec 31, 2021 | -$18.45M | – |
| FY2020 | Dec 31, 2020 | -$22.59M | – |
| FY2019 | Dec 31, 2019 | -$17.24M | -268.2% |
| FY2018 | Dec 31, 2018 | $10.25M | – |
| FY2017 | Dec 31, 2017 | -$4.86M | – |
| FY2016 | Dec 31, 2016 | -$13.07M | – |
| FY2015 | Dec 31, 2015 | -$11.21M | – |
| FY2014 | Dec 31, 2014 | -$8.55M | – |
| FY2013 | Dec 31, 2013 | -$1.62M | – |
| FY2012 | Dec 31, 2012 | -$43.02K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $377.00K | – |
| Q2 FY2026 | Jun 30, 2026 | -$301.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$318.00K | -2990.9% |
| Q4 FY2025 | Dec 31, 2025 | -$75.00K | – |
| Q3 FY2025 | Sep 30, 2025 | -$275.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$131.00K | – |
| Q1 FY2025 | Mar 31, 2025 | $11.00K | – |
| Q4 FY2024 | Dec 31, 2024 | -$646.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$341.00K | – |
| Q2 FY2024 | Jun 30, 2024 | -$583.00K | – |
| Q1 FY2024 | Mar 31, 2024 | -$620.00K | -110.8% |
| Q4 FY2023 | Dec 31, 2023 | -$889.00K | – |
| Q3 FY2023 | Sep 30, 2023 | -$437.00K | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.08M | – |
| Q1 FY2023 | Mar 31, 2023 | $5.76M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.13M | – |
| Q3 FY2022 | Sep 30, 2022 | -$892.00K | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.32M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.52M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.84M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.98M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.51M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.11M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.46M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.15M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.66M | -471.4% |
| Q1 FY2020 | Mar 31, 2020 | -$5.32M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.34M | -366.3% |
| Q3 FY2019 | Sep 30, 2019 | -$1.77M | -150.3% |
| Q2 FY2019 | Jun 30, 2019 | $1.25M | -62.0% |
| Q1 FY2019 | Mar 31, 2019 | -$9.38M | -1503.9% |
| Q4 FY2018 | Dec 31, 2018 | $2.76M | +1938.1% |
| Q3 FY2018 | Sep 30, 2018 | $3.53M | – |
| Q2 FY2018 | Jun 30, 2018 | $3.30M | – |
| Q1 FY2018 | Mar 31, 2018 | $668.00K | – |
| Q4 FY2017 | Dec 31, 2017 | $135.28K | – |
| Q3 FY2017 | Sep 30, 2017 | -$481.78K | – |
| Q2 FY2017 | Jun 30, 2017 | -$859.67K | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.65M | – |
| Q4 FY2016 | Dec 31, 2016 | -$8.23M | – |
See a number that looks wrong?